ATF6 and Miyoshi myopathy: <b>Results:</b> Carfilzomib-adapted MM cell lines demonstrated reduced levels of u<i>XBP1</i>, <i>ATF6</i>, and <i>LAMP2A</i> mRNA compared to treatment-naïve cells.